NO20090830L - Exendin fusjonsproteiner - Google Patents

Exendin fusjonsproteiner

Info

Publication number: NO20090830L
Authority: NO; Norway
Prior art keywords: fusion proteins; exendin; exendin fusion; transferrin; obesity
Prior art date: 2006-07-24

Application number

NO20090830A

Other languages

English (en)

Norwegian (no)

Inventor

Homayoun Sadeghi

Christopher Philip Prior

David James Ballance

Andrew John Turner

Original Assignee

Biorexis Pharmaceutical Corp

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2006-07-24

Filing date

2009-02-23

Publication date

2009-03-02

2009-02-23 Application filed by Biorexis Pharmaceutical Corp filed Critical Biorexis Pharmaceutical Corp

2009-03-02 Publication of NO20090830L publication Critical patent/NO20090830L/no

Links

102000037865 fusion proteins Human genes 0.000 title abstract 3
108020001507 fusion proteins Proteins 0.000 title abstract 3
108010011459 Exenatide Proteins 0.000 abstract 2
JUFFVKRROAPVBI-PVOYSMBESA-N chembl1210015 Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(=O)N[C@H]1[C@@H]([C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO[C@]3(O[C@@H](C[C@H](O)[C@H](O)CO)[C@H](NC(C)=O)[C@@H](O)C3)C(O)=O)O2)O)[C@@H](CO)O1)NC(C)=O)C(=O)NCC(=O)NCC(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CO)C(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 JUFFVKRROAPVBI-PVOYSMBESA-N 0.000 abstract 2
229960001519 exenatide Drugs 0.000 abstract 2
208000008589 Obesity Diseases 0.000 abstract 1
102000004338 Transferrin Human genes 0.000 abstract 1
108090000901 Transferrin Proteins 0.000 abstract 1
230000037396 body weight Effects 0.000 abstract 1
102000039446 nucleic acids Human genes 0.000 abstract 1
108020004707 nucleic acids Proteins 0.000 abstract 1
150000007523 nucleic acids Chemical class 0.000 abstract 1
235000020824 obesity Nutrition 0.000 abstract 1
239000008194 pharmaceutical composition Substances 0.000 abstract 1
229920001184 polypeptide Polymers 0.000 abstract 1
108090000765 processed proteins & peptides Proteins 0.000 abstract 1
102000004196 processed proteins & peptides Human genes 0.000 abstract 1
239000012581 transferrin Substances 0.000 abstract 1
208000001072 type 2 diabetes mellitus Diseases 0.000 abstract 1
239000013598 vector Substances 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/57563—Vasoactive intestinal peptide [VIP]; Related peptides
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
- A61P5/04—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin for decreasing, blocking or antagonising the activity of the hypothalamic hormones
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/62—DNA sequences coding for fusion proteins
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Genetics & Genomics (AREA)
Biomedical Technology (AREA)
Diabetes (AREA)
Endocrinology (AREA)
Zoology (AREA)
Molecular Biology (AREA)
Biochemistry (AREA)
Biophysics (AREA)
Neurology (AREA)
General Engineering & Computer Science (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Wood Science & Technology (AREA)
Biotechnology (AREA)
Neurosurgery (AREA)
Gastroenterology & Hepatology (AREA)
Obesity (AREA)
Vascular Medicine (AREA)
Hematology (AREA)
Plant Pathology (AREA)
Toxicology (AREA)
Physics & Mathematics (AREA)
Heart & Thoracic Surgery (AREA)
Cardiology (AREA)
Microbiology (AREA)
Psychology (AREA)

NO20090830A 2006-07-24 2009-02-23 Exendin fusjonsproteiner NO20090830L (no)

Applications Claiming Priority (4)

Application Number	Priority Date	Filing Date	Title
US83258206P	2006-07-24	2006-07-24
US85747406P	2006-11-08	2006-11-08
US87496506P	2006-12-15	2006-12-15
PCT/IB2007/002047 WO2008012629A2 (en)	2006-07-24	2007-07-13	Exendin fusion proteins

Publications (1)

Publication Number	Publication Date
NO20090830L true NO20090830L (no)	2009-03-02

Family

ID=38917401

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO20090830A NO20090830L (no)	2006-07-24	2009-02-23	Exendin fusjonsproteiner

Country Status (22)

Country	Link
US (2)	US7867972B2 (de)
EP (1)	EP2046826B1 (de)
JP (1)	JP5102833B2 (de)
KR (1)	KR101193722B1 (de)
CN (1)	CN101511868B (de)
AR (1)	AR062030A1 (de)
AT (1)	ATE524493T1 (de)
AU (1)	AU2007278994B2 (de)
CA (1)	CA2658654A1 (de)
CL (1)	CL2007002157A1 (de)
DK (1)	DK2046826T3 (de)
ES (1)	ES2371495T3 (de)
GT (1)	GT200700059A (de)
IL (1)	IL196674A (de)
MX (1)	MX2009001066A (de)
NO (1)	NO20090830L (de)
PA (1)	PA8738401A1 (de)
PE (1)	PE20080733A1 (de)
TW (1)	TW200821327A (de)
UY (1)	UY30497A1 (de)
WO (1)	WO2008012629A2 (de)
ZA (1)	ZA200901280B (de)

Families Citing this family (106)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CN1747747B (zh)	2003-01-06	2012-09-05	安吉奥开米公司	作为穿过血脑屏障的载体的抑酶肽及类似物
CN101160403B (zh)	2005-02-18	2014-08-13	安吉奥开米公司	转运化合物穿过血脑屏障的分子
JP5436856B2 (ja)	2005-07-15	2014-03-05	アンジオケムインコーポレーティッド	薬学的複合体における担体としてのアプロチニンポリペプチドの使用
US7855279B2 (en)	2005-09-27	2010-12-21	Amunix Operating, Inc.	Unstructured recombinant polymers and uses thereof
ES2535358T3 (es)	2006-12-12	2015-05-08	Biorexis Pharmaceutical Corporation	Bibliotecas de proteínas de fusión de transferrina
US9365634B2 (en)	2007-05-29	2016-06-14	Angiochem Inc.	Aprotinin-like polypeptides for delivering agents conjugated thereto to tissues
GB0711424D0 (en) *	2007-06-13	2007-07-25	Novozymes Delta Ltd	Recombinant transferrin mutants
US8921314B2 (en)	2008-10-15	2014-12-30	Angiochem, Inc.	Conjugates of GLP-1 agonists and uses thereof
MX2011005963A (es)	2008-12-05	2011-09-01	Angiochem Inc	Conjugados de neurotensina o analogos de neurotensina y sus usos.
CN102348723A (zh) *	2008-12-05	2012-02-08	安吉奥开米公司	肽治疗剂轭合物及其应用
CN102300987A (zh)	2008-12-17	2011-12-28	安吉奥开米公司	膜型-1基质金属蛋白抑制剂及其用途
CN108530543B (zh)	2009-02-03	2023-06-23	阿穆尼克斯制药公司	延伸重组多肽和包含该延伸重组多肽的组合物
AU2010239069B2 (en)	2009-04-20	2015-05-14	Angiochem Inc	Treatment of ovarian cancer using an anticancer agent conjugated to an Angiopep-2 analog
JP5839597B2 (ja)	2009-06-08	2016-01-06	アムニクスオペレーティングインコーポレイテッド	グルコース調節ポリペプチド並びにその作成及び使用方法
MX2012000016A (es)	2009-07-02	2012-03-26	Angiochem Inc	Conjugados de peptidos multimericos y sus usos.
US20120148586A1 (en)	2009-08-27	2012-06-14	Joyce Ching Tsu Chou	Glucagon-like protein-1 receptor (glp-1r) agonists for treating autoimmune disorders
KR101259074B1 (ko) *	2010-11-23	2013-04-29	서울대학교산학협력단	분비신호펩타이드가 연결된 엑센딘-4를 도입한 췌장소도세포 및 이를 이용한 당뇨병 치료방법
CA2833623A1 (en) *	2011-04-20	2012-10-26	The United States Of America, As Represented By The Secretary, Department Of Health And Human Services	Aav mediated exendin-4 gene transfer to salivary glands to protect subjects from diabetes or obesity
JP6006309B2 (ja) *	2011-07-08	2016-10-12	アミリン・ファーマシューティカルズ, リミテッド・ライアビリティ・カンパニーAmylin Pharmaceuticals, Llc	作用持続期間が増大し、免疫原性が減少した操作されたポリペプチド
EP2770991B9 (de) *	2011-10-24	2017-01-25	The Trustees Of The University Of Pennsylvania	Oral verabreichtes plastidexprimiertes choleratoxin-b-untereinheit-exendin 4 zur verwendung in der behandlung von typ-2-diabetes
WO2013120022A2 (en) *	2012-02-08	2013-08-15	Seneb Biosciences, Inc.	Treatment of hypoglycemia
CN102618552B (zh) *	2012-04-01	2014-08-20	东莞市麦亘生物科技有限公司	一种重组艾塞那肽的生产工艺
US20130323221A1 (en)	2012-05-30	2013-12-05	Biostrategies LC	Plant lectins as carriers of associated drug substances into animal and human cells
US10441665B2 (en)	2012-07-25	2019-10-15	Hanmi Pharm. Co., Ltd.	Liquid formulation of long acting insulinotropic peptide conjugate
AR094821A1 (es)	2012-07-25	2015-09-02	Hanmi Pharm Ind Co Ltd	Formulación líquida de un conjugado de péptido insulinotrópico de acción prolongada
CN102776148A (zh) *	2012-08-28	2012-11-14	中国林业科学研究院资源昆虫研究所	一种昆虫细胞生长用培养基
DK2890791T3 (da)	2012-08-31	2019-06-11	Us Health	Aav-medieret aquaporingenoverførsel til behandling af sjögrens syndrom
UA116217C2 (uk)	2012-10-09	2018-02-26	Санофі	Пептидна сполука як подвійний агоніст рецепторів glp1-1 та глюкагону
JP2016506401A (ja)	2012-12-21	2016-03-03	サノフイ	二重ｇｌｐ１／ｇｉｐまたは三方ｇｌｐ１／ｇｉｐ／グルカゴンアゴニストとしてのエキセンジン−４誘導体
WO2014164670A1 (en)	2013-03-13	2014-10-09	Emory University	Protein particles comprising disulfide crosslinkers and uses related thereto
CN103204944B (zh) *	2013-03-26	2014-05-28	江苏健德生物药业有限公司	用于治疗糖尿病的长效免疫融合蛋白
CN104513309A (zh) *	2013-09-26	2015-04-15	上海亨臻实业有限公司	一种蛋白功能结构域铰链肽及其用途
SI3063275T1 (sl)	2013-10-31	2020-02-28	Resolve Therapeutics, Llc	Terapevtske fuzije nukleaza-albumin in postopki
TW201609796A (zh)	2013-12-13	2016-03-16	賽諾菲公司	非醯化之艾塞那肽－４（ｅｘｅｎｄｉｎ－４）胜肽類似物
TW201609799A (zh)	2013-12-13	2016-03-16	賽諾菲公司	雙重ｇｌｐ－１／ｇｉｐ受體促效劑
WO2015086733A1 (en)	2013-12-13	2015-06-18	Sanofi	Dual glp-1/glucagon receptor agonists
EP3080150B1 (de)	2013-12-13	2018-08-01	Sanofi	Exendin-4-peptidanaloga als duale glp-1/gip-rezeptoragonisten
TW201625670A (zh)	2014-04-07	2016-07-16	賽諾菲公司	衍生自ｅｘｅｎｄｉｎ－４之雙重ｇｌｐ－１／升糖素受體促效劑
TW201625668A (zh)	2014-04-07	2016-07-16	賽諾菲公司	作為胜肽性雙重ｇｌｐ－１／昇糖素受體激動劑之艾塞那肽－４衍生物
TW201625669A (zh)	2014-04-07	2016-07-16	賽諾菲公司	衍生自艾塞那肽－４（Ｅｘｅｎｄｉｎ－４）之肽類雙重ＧＬＰ－１／升糖素受體促效劑
US9932381B2 (en)	2014-06-18	2018-04-03	Sanofi	Exendin-4 derivatives as selective glucagon receptor agonists
WO2016025642A1 (en)	2014-08-12	2016-02-18	Massachusetts Institute Of Technology	Synergistic tumor treatment with il-2 and integrin-binding-fc-fusion protein
WO2016025647A1 (en)	2014-08-12	2016-02-18	Massachusetts Institute Of Technology	Synergistic tumor treatment with il-2, a therapeutic antibody, and a cancer vaccine
AR105319A1 (es)	2015-06-05	2017-09-27	Sanofi Sa	Profármacos que comprenden un conjugado agonista dual de glp-1 / glucagón conector ácido hialurónico
US10980892B2 (en)	2015-06-15	2021-04-20	Angiochem Inc.	Methods for the treatment of leptomeningeal carcinomatosis
TW201706291A (zh)	2015-07-10	2017-02-16	賽諾菲公司	作為選擇性肽雙重ｇｌｐ－１／升糖素受體促效劑之新毒蜥外泌肽（ｅｘｅｎｄｉｎ－４）衍生物
CN106519038B (zh) *	2015-09-15	2019-12-27	香港中文大学深圳研究院	一种融合蛋白、其生产方法及转基因水稻的生产方法
EP3423077A4 (de)	2016-03-01	2019-11-13	Biostrategies LC	Materialien und verfahren zur minderung der immunsensibilisierung
EP3468576B1 (de)	2016-04-15	2023-06-07	Syracuse University	Verbesserung eines peptidwirkstoffes mit vitamin b12 und haptocorrinbindenden substratkonjugaten
CN106397600A (zh) *	2016-06-24	2017-02-15	中国药科大学	一种具有降血糖活性和透皮能力的重组融合蛋白、编码基因及其应用
AU2017290389B2 (en)	2016-07-01	2024-09-26	Resolve Therapeutics, Llc	Optimized binuclease fusions and methods
US10350266B2 (en)	2017-01-10	2019-07-16	Nodus Therapeutics, Inc.	Method of treating cancer with a multiple integrin binding Fc fusion protein
US10603358B2 (en)	2017-01-10	2020-03-31	Nodus Therapeutics	Combination tumor treatment with an integrin-binding-Fc fusion protein and immune stimulator
US11485781B2 (en)	2017-08-17	2022-11-01	Massachusetts Institute Of Technology	Multiple specificity binders of CXC chemokines
US10947295B2 (en)	2017-08-22	2021-03-16	Sanabio, Llc	Heterodimers of soluble interferon receptors and uses thereof
EP3681909A1 (de) *	2017-09-14	2020-07-22	Denali Therapeutics Inc.	Anti-trem2-antikörper und verfahren zur verwendung davon
TW201934573A (zh) *	2018-01-10	2019-09-01	美商戴納立製藥公司	轉鐵蛋白受體結合性多肽及其用途
AU2019219200B2 (en)	2018-02-12	2025-02-13	BioNTech SE	Treatment using cytokine encoding RNA
EP3810186B1 (de)	2018-06-21	2022-09-28	Novo Nordisk A/S	Neuartige verbindungen zur behandlung von adipositas
JP7550745B2 (ja)	2018-07-24	2024-09-13	バイオエヌテックエスエー	Ｉｌ２アゴニスト
AU2019346335B2 (en)	2018-09-28	2024-07-25	Massachusetts Institute Of Technology	Collagen-localized immunomodulatory molecules and methods thereof
JP7499257B2 (ja)	2019-01-04	2024-06-13	リゾルブセラピューティクス，エルエルシー	ヌクレアーゼ融合タンパク質によるシェーグレン病の処置
WO2020146807A1 (en) *	2019-01-10	2020-07-16	Precision Biosciences, Inc.	Genetically-modified cells comprising a modified transferrin gene
WO2020154032A1 (en)	2019-01-23	2020-07-30	Massachusetts Institute Of Technology	Combination immunotherapy dosing regimen for immune checkpoint blockade
KR20210124236A (ko)	2019-02-08	2021-10-14	비온테크 쎌 & 제네 테라피스 게엠베하	Car-조작된 t 세포 및 사이토카인을 수반한 치료
AU2020242254B2 (en)	2019-03-18	2026-03-12	Biontech Cell & Gene Therapies Gmbh	Interleukin-2 receptor (il2r) and interleukin-2 (il2) variants for specific activation of immune effector cells
WO2020200481A1 (en)	2019-04-05	2020-10-08	Biontech Rna Pharmaceuticals Gmbh	Treatment involving interleukin-2 (il2) and interferon (ifn)
TW202115105A (zh)	2019-06-24	2021-04-16	德商拜恩迪克Ｒｎａ製藥有限公司	Ｉｌ２激動劑
CN115380043A (zh) *	2019-08-13	2022-11-22	安医健有限公司	艾塞那肽类似物及其用途
WO2021058091A1 (en)	2019-09-24	2021-04-01	Biontech Rna Pharmaceuticals Gmbh	Treatment involving therapeutic antibody and interleukin-2 (il2)
WO2021129927A1 (en)	2019-12-23	2021-07-01	Biontech Cell & Gene Therapies Gmbh	Treatment with immune effector cells engineered to express an antigen receptor
WO2021129945A1 (en)	2019-12-27	2021-07-01	Biontech Cell & Gene Therapies Gmbh	In vitro and in vivo gene delivery to immune effector cells using nanoparticles functionalized with designed ankyrin repeat proteins (darpins)
CA3171370A1 (en)	2020-03-16	2021-09-23	Ugur Sahin	Antigen-specific t cell receptors and t cell epitopes
WO2021197589A1 (en)	2020-03-31	2021-10-07	BioNTech SE	Treatment involving non-immunogenic rna for antigen vaccination
EP4171614A1 (de)	2020-06-29	2023-05-03	Resolve Therapeutics, LLC	Behandlung des sjögren-syndroms mit nukleasefusionsproteinen
WO2022135666A1 (en)	2020-12-21	2022-06-30	BioNTech SE	Treatment schedule for cytokine proteins
TW202245808A (zh)	2020-12-21	2022-12-01	德商拜恩迪克公司	用於治療癌症之治療性ｒｎａ
WO2022135667A1 (en)	2020-12-21	2022-06-30	BioNTech SE	Therapeutic rna for treating cancer
AU2022256732A1 (en)	2021-04-12	2023-10-19	Biontech Delivery Technologies Gmbh	Rna compositions comprising a buffer substance and methods for preparing, storing and using the same
CN117750974A (zh)	2021-04-20	2024-03-22	生物技术欧洲股份公司	病毒疫苗
WO2022261191A1 (en)	2021-06-08	2022-12-15	University Of Georgia Research Foundation, Inc.	Nanoparticles for treating prostate cancer
WO2022261186A1 (en) *	2021-06-08	2022-12-15	University Of Georgia Research Foundation, Inc.	Nanoparticles for preventing peri/post-menopausal bone loss and/or obesity
US12521354B2 (en)	2021-06-08	2026-01-13	University Of Georgia Research Foundation, Inc.	Nanoparticles for targeted non-surgical spaying and neutering
WO2023051926A1 (en)	2021-09-30	2023-04-06	BioNTech SE	Treatment involving non-immunogenic rna for antigen vaccination and pd-1 axis binding antagonists
AU2021470029A1 (en)	2021-10-21	2024-05-02	BioNTech SE	Coronavirus vaccine
WO2023067193A2 (en)	2021-10-22	2023-04-27	BioNTech SE	Compositions for administration of different doses of rna
WO2023083434A1 (en)	2021-11-09	2023-05-19	BioNTech SE	Rna encoding peptidoglycan hydrolase and use thereof for treating bacterial infection
WO2023126053A1 (en)	2021-12-28	2023-07-06	BioNTech SE	Lipid-based formulations for administration of rna
WO2023165681A1 (en)	2022-03-01	2023-09-07	BioNTech SE	Rna lipid nanoparticles (lnps) comprising a polyoxazoline and/or polyoxazine polymer
WO2023193892A1 (en)	2022-04-05	2023-10-12	BioNTech SE	Nucleic acid compositions comprising an inorganic polyphosphate and methods for preparing, storing and using the same
WO2024002985A1 (en)	2022-06-26	2024-01-04	BioNTech SE	Coronavirus vaccine
WO2024017479A1 (en)	2022-07-21	2024-01-25	BioNTech SE	Multifunctional cells transiently expressing an immune receptor and one or more cytokines, their use and methods for their production
AU2023317702A1 (en)	2022-08-01	2025-01-09	BioNTech SE	Nucleic acid compositions comprising amphiphilic oligo ethylene glycol (oeg)-conjugated compounds and methods of using such compounds and compositions
US20260048110A1 (en)	2022-08-03	2026-02-19	BioNTech SE	Rna for preventing or treating tuberculosis
WO2024027910A1 (en)	2022-08-03	2024-02-08	BioNTech SE	Rna for preventing or treating tuberculosis
WO2024153324A1 (en)	2023-01-18	2024-07-25	BioNTech SE	Rna formulations for pharmaceutical use
WO2024213776A1 (en)	2023-04-14	2024-10-17	BioNTech SE	Rna for preventing or treating tuberculosis
CN121398842A (zh)	2023-04-14	2026-01-23	百欧恩泰欧洲股份公司	用于预防或治疗结核病的rna
EP4694919A1 (de)	2023-04-14	2026-02-18	BioNTech SE	Rna zur vorbeugung oder behandlung von tuberkulose
WO2025006676A2 (en)	2023-06-27	2025-01-02	Firecyte Therapeutics, Inc.	Insulin-like growth factor binding protein like 1 (igfbpl1) compositions and methods of use thereof
WO2025021277A1 (en)	2023-07-21	2025-01-30	BioNTech SE	Agents and methods for targeted delivery of cytokines to immune cells
KR20260044219A (ko)	2023-07-21	2026-04-01	매로우 테라퓨틱스, 인크.	조혈 세포 표적화 접합체 및 관련 방법
WO2025026866A1 (en)	2023-07-28	2025-02-06	BioNTech SE	Rna therapeutics with reduced toxicity
TW202539697A (zh)	2023-11-15	2025-10-16	德商拜恩技術股份公司	冠狀病毒疫苗
WO2025147696A1 (en)	2024-01-05	2025-07-10	Resolve Therapeutics, Llc	Treatment of symptoms associated with sars-cov viral infection or a prior sars-cov viral infection with nuclease agents
WO2026082899A2 (en)	2024-10-16	2026-04-23	BioNTech SE	Rna for preventing or treating tuberculosis

Family Cites Families (101)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4289689A (en) *	1980-03-14	1981-09-15	Hoffmann-La Roche Inc.	Preparation of homogeneous human fibroblast interferon
DE3273787D1 (en) *	1981-02-04	1986-11-20	Japan Found Cancer	Human interferon-beta gene
US4599311A (en)	1982-08-13	1986-07-08	Kawasaki Glenn H	Glycolytic promotersfor regulated protein expression: protease inhibitor
US4816449A (en) *	1984-08-09	1989-03-28	Immunetech Pharmaceuticals	Immunotherapeutic anti-inflammatory peptide agents
AU600885B2 (en)	1984-05-25	1990-08-30	Zymogenetics Inc.	Stable DNA constructs
DE3546807C2 (de)	1985-03-30	1991-03-28	Marc Genf/Geneve Ch Ballivet
US6492107B1 (en)	1986-11-20	2002-12-10	Stuart Kauffman	Process for obtaining DNA, RNA, peptides, polypeptides, or protein, by recombinant DNA technique
US5026651A (en) *	1985-04-25	1991-06-25	Board Of Regents, The University Of Texas System	Methods and compositions for the production of human transferrin
US5262177A (en) *	1986-02-07	1993-11-16	Oncogen	Recombinant viruses encoding the human melanoma-associated antigen
GB8620926D0 (en)	1986-08-29	1986-10-08	Delta Biotechnology Ltd	Yeast promoter
US5260203A (en) *	1986-09-02	1993-11-09	Enzon, Inc.	Single polypeptide chain binding molecules
EP0286424B1 (de)	1987-04-09	1994-03-16	Delta Biotechnology Limited	Hefevektor
US5091513A (en) *	1987-05-21	1992-02-25	Creative Biomolecules, Inc.	Biosynthetic antibody binding sites
PT88641B (pt)	1987-10-02	1993-04-30	Genentech Inc	Metodo para a preparacao de uma variante de adesao
GB8726953D0 (en)	1987-11-18	1987-12-23	Delta Biotechnology Ltd	Yeast expression system
US6018026A (en)	1988-01-22	2000-01-25	Zymogenetics, Inc.	Biologically active dimerized and multimerized polypeptide fusions
AU633020B2 (en)	1988-07-23	1993-01-21	Novozymes Delta Limited	New secretory leader sequences
GB8820951D0 (en)	1988-09-07	1988-10-05	Delta Biotechnology Ltd	Fermentation method
US5260202A (en)	1988-09-07	1993-11-09	Delta Biotechnology Limited	Fermentation method
US5571691A (en) *	1989-05-05	1996-11-05	Baylor College Of Medicine	Production of recombinant lactoferrin and lactoferrin polypeptides using CDNA sequences in various organisms
JP2877509B2 (ja)	1989-05-19	1999-03-31	アムジエン・インコーポレーテツド	メタロプロテイナーゼ阻害剤
GB8927480D0 (en)	1989-12-05	1990-02-07	Delta Biotechnology Ltd	Mutant fungal strain detection and new promoter
EP0413662A3 (en)	1989-08-15	1991-10-23	Ciba-Geigy Ag	Polyaryleneethers
US5672683A (en)	1989-09-07	1997-09-30	Alkermes, Inc.	Transferrin neuropharmaceutical agent fusion protein
US5977307A (en) *	1989-09-07	1999-11-02	Alkermes, Inc.	Transferrin receptor specific ligand-neuropharmaceutical agent fusion proteins
US5667986A (en)	1989-10-18	1997-09-16	Delta Biotechnology Limited	Yeast promoter for expressing heterologous polypeptides
GB8923521D0 (en)	1989-10-18	1989-12-06	Delta Biotechnology Ltd	Yeast promoter
GB8928874D0 (en)	1989-12-21	1990-02-28	Celltech Ltd	Humanised antibodies
US5545618A (en) *	1990-01-24	1996-08-13	Buckley; Douglas I.	GLP-1 analogs useful for diabetes treatment
US6066469A (en) *	1990-03-08	2000-05-23	Ferro Dynamics, Inc.	Cloning, expression, and uses of human lactoferrin
US5723286A (en) *	1990-06-20	1998-03-03	Affymax Technologies N.V.	Peptide library and screening systems
US6825037B1 (en) *	1991-02-08	2004-11-30	University Of Vermont	Recombinant transferrins, transferrin half-molecules and mutants thereof
US5986067A (en)	1991-02-08	1999-11-16	The University Of Vermont And State Agricultural College	Recombinant transferrins, transferrin half-molecules and mutants thereof
US5656272A (en) *	1991-03-18	1997-08-12	New York University Medical Center	Methods of treating TNF-α-mediated Crohn's disease using chimeric anti-TNF antibodies
EP0603187A4 (en) *	1991-05-31	1995-08-30	Us Health	Human lactoferrin.
FR2686899B1 (fr) *	1992-01-31	1995-09-01	Rhone Poulenc Rorer Sa	Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant.
ZA932568B (en) *	1992-04-24	1993-11-12	Baylor College Midecine A Non	Production of recombinant human lactoferrin
DE4244915C2 (de)	1992-08-14	1998-12-03	Widmar Prof Dr Tanner	DNA-Moleküle codierend Proteine, die an der O-Glykosylierung von Proteinen beteiligt sind
US5728553A (en)	1992-09-23	1998-03-17	Delta Biotechnology Limited	High purity albumin and method of producing
EP0599303A3 (de) *	1992-11-27	1998-07-29	Takeda Chemical Industries, Ltd.	Peptide-Konjugate
US5547871A (en)	1993-01-25	1996-08-20	American Cyanamid Company	Heterologous signal sequences for secretion of insect controlling proteins
US5424286A (en) *	1993-05-24	1995-06-13	Eng; John	Exendin-3 and exendin-4 polypeptides, and pharmaceutical compositions comprising same
US5464933A (en) *	1993-06-07	1995-11-07	Duke University	Synthetic peptide inhibitors of HIV transmission
US5840707A (en)	1993-10-04	1998-11-24	Albany Medical College	Stabilizing and delivery means of biological molecules
GB9404270D0 (en)	1994-03-05	1994-04-20	Delta Biotechnology Ltd	Yeast strains and modified albumins
GB9411356D0 (en)	1994-06-07	1994-07-27	Delta Biotechnology Ltd	Yeast strains
US6524557B1 (en)	1994-12-22	2003-02-25	Astrazeneca Ab	Aerosol formulations of peptides and proteins
US5843882A (en) *	1995-04-27	1998-12-01	The United States Of America As Represented By The Department Of Health And Human Services	Antiviral proteins and peptides
US5817789A (en) *	1995-06-06	1998-10-06	Transkaryotic Therapies, Inc.	Chimeric proteins for use in transport of a selected substance into cells
US7285526B2 (en) *	1995-07-14	2007-10-23	Meiogen Biotechnology Corporation	Interferon antagonists useful for the treatment of interferon related diseases
US5925351A (en) *	1995-07-21	1999-07-20	Biogen, Inc.	Soluble lymphotoxin-β receptors and anti-lymphotoxin receptor and ligand antibodies as therapeutic agents for the treatment of immunological disease
US5849293A (en) *	1996-01-11	1998-12-15	Cornell Research Foundation, Inc.	Use of human transferrin in controlling insulin levels
WO1997033973A1 (en)	1996-03-13	1997-09-18	Delta Biotechnology Limited	Fermentation control
DE69739172D1 (de) *	1996-08-08	2009-01-29	Amylin Pharmaceuticals Inc	Regulation gastrointestinaler beweglichkeit
US7235627B2 (en) *	1996-08-30	2007-06-26	Novo Nordisk A/S	Derivatives of GLP-1 analogs
US6458924B2 (en) *	1996-08-30	2002-10-01	Novo Nordisk A/S	Derivatives of GLP-1 analogs
UA65549C2 (uk) *	1996-11-05	2004-04-15	Елі Ліллі Енд Компані	Спосіб регулювання ожиріння шляхом периферійного введення аналогів та похідних glp-1 (варіанти) та фармацевтична композиція
ES2237790T3 (es) *	1996-11-12	2005-08-01	Novo Nordisk A/S	Uso de peptidos glp-1.
PT1629849E (pt) *	1997-01-07	2013-07-09	Amylin Pharmaceuticals Llc	Composições farmacêuticas que compreendem exendinas e seus agonistas
US6723530B1 (en) *	1997-02-05	2004-04-20	Amylin Pharmaceuticals, Inc.	Polynucleotides encoding proexendin, and methods and uses thereof
HUP0001272A3 (en)	1997-04-16	2012-12-28	Unigene Lab Inc	Direct expression of peptides into culture media
GB9713412D0 (en)	1997-06-26	1997-08-27	Delta Biotechnology Ltd	Improved protein expression strains
JP5377806B2 (ja)	1997-09-26	2013-12-25	アサーシス，インコーポレイテッド	ベクター構築物の細胞ｄｎａとの非相同組換えによる内因性遺伝子の発現
DK0978565T3 (da)	1998-01-30	2008-02-04	Asubio Pharma Co Ltd	Fremgangsmåde til fremstilling af peptid under anvendelse af et hjælperpeptid
AU2610899A (en)	1998-02-27	1999-09-15	Novo Nordisk A/S	N-terminally modified glp-1 derivatives
AU757658B2 (en)	1998-03-09	2003-02-27	Zealand Pharma A/S	Pharmacologically active peptide conjugates having a reduced tendency towards enzymatic hydrolysis
US6998387B1 (en) *	1998-03-19	2006-02-14	Amylin Pharmaceuticals, Inc.	Human appetite control by glucagon-like peptide receptor binding compounds
US6258782B1 (en) *	1998-05-20	2001-07-10	Trimeris, Inc.	Hybrid polypeptides with enhanced pharmacokinetic properties
GB9902000D0 (en)	1999-01-30	1999-03-17	Delta Biotechnology Ltd	Process
SI1180121T1 (en) *	1999-05-17	2004-04-30	Conjuchem, Inc.	Long lasting insulinotropic peptides
WO2000069917A1 (fr) *	1999-05-18	2000-11-23	Maruho Kabushikikaisha	Compositions medicinales destinees a inhiber le systeme kallikreine-kinine ou la phospholipase a¿2?
US20030235884A1 (en) *	1999-06-15	2003-12-25	Cummings Richard D.	Polynucleotides encoding core 1 beta3-galactosyl transferase and methods of use thereof
EP1076066A1 (de)	1999-07-12	2001-02-14	Zealand Pharmaceuticals A/S	Peptide zur Senkung des Blutglukosespiegels
JP2003514532A (ja)	1999-11-19	2003-04-22	トランスカーヨティックセラピーズインコーポレイテッド	生成物の産生量を最適化するための核酸構築体
US6380362B1 (en) *	1999-12-23	2002-04-30	Genesis Research & Development Corporation Ltd.	Polynucleotides, polypeptides expressed by the polynucleotides and methods for their use
EP1244701A1 (de)	1999-12-23	2002-10-02	Human Genome Sciences, Inc.	Transferrin polynukleotide, polypeptide und antikörper
US6420346B1 (en) *	2000-02-07	2002-07-16	Rappaport Family Institute For Research In The Medical Sciences	Polynucleotides encoding MIP-1α, MCP-1, MIP-1β, Rantes and TNF-α, and methods for treating rheumatoid arthritis
EP1274720A4 (de)	2000-04-12	2004-08-18	Human Genome Sciences Inc	Albumin enthaltende fusionsproteine
WO2002021141A2 (en) *	2000-09-06	2002-03-14	Aventis Pharma S.A.	Methods and compositions for diseases associated with amyloidosis
ES2311560T3 (es)	2000-12-07	2009-02-16	Eli Lilly And Company	Proteinas de fusion glp-1.
CN1363654A (zh)	2001-07-19	2002-08-14	上海华谊生物技术有限公司	生产促胰岛素分泌肽glp－1(7－36)的基因工程菌以及生产glp－1(7－36)的方法
US7176278B2 (en) *	2001-08-30	2007-02-13	Biorexis Technology, Inc.	Modified transferrin fusion proteins
WO2004019872A2 (en) *	2002-08-30	2004-03-11	Biorexis Pharmaceutical Corporation	Oral delivery of modified transferrin fusion proteins
US20030226155A1 (en) *	2001-08-30	2003-12-04	Biorexis Pharmaceutical Corporation	Modified transferrin-antibody fusion proteins
BR0212256A (pt)	2001-08-30	2004-08-31	Biorexis Pharmaceutical Corp	Proteìnas de fusão de transferrina modificadas
US20030232761A1 (en)	2002-03-28	2003-12-18	Hinke Simon A.	Novel analogues of glucose-dependent insulinotropic polypeptide
US20060105387A1 (en) *	2002-08-30	2006-05-18	Prior Christopher P	Transferrin fusion proteins libraries
US20060130158A1 (en)	2002-08-30	2006-06-15	Turner Andrew J	Modified transferrin fusion proteins comprising duplicate transferrin amino or carboxy terminal domains
WO2004020588A2 (en)	2002-08-30	2004-03-11	Biorexis Pharmaceutical Corporation	Transferrin fusion protein libraries
CA2510199A1 (en)	2002-12-17	2004-07-08	Nastech Pharmaceutical Company Inc.	Compositions and methods for enhanced mucosal delivery of y2 receptor-binding peptides and methods for treating and preventing obesity
US7186692B2 (en)	2002-12-17	2007-03-06	Nastech Pharmaceutical Company Inc.	Compositions and methods for enhanced mucosal delivery and non-infused administration of Y2 receptor-binding peptides and methods for treating and preventing obesity
WO2004078777A2 (en)	2003-03-04	2004-09-16	Biorexis Pharmaceutical Corporation	Dipeptidyl-peptidase protected proteins
US20070060512A1 (en) *	2003-03-04	2007-03-15	Homayoun Sadeghi	Dipeptidyl-peptidase protected protein
NZ543274A (en)	2003-05-14	2007-12-21	Emisphere Tech Inc	Compositions for delivering peptide YY and PYY agonists
ES2425221T3 (es)	2003-05-30	2013-10-14	Amylin Pharmaceuticals, Llc	Nuevos métodos y composiciones para suministro por vía transmucosa potenciado de péptidos y proteínas
WO2005021579A2 (en)	2003-08-28	2005-03-10	Biorexis Pharmaceutical Corporation	Epo mimetic peptides and fusion proteins
US20060205037A1 (en)	2003-08-28	2006-09-14	Homayoun Sadeghi	Modified transferrin fusion proteins
GB0329681D0 (en)	2003-12-23	2004-01-28	Delta Biotechnology Ltd	Gene expression technique
ZA200701484B (en) *	2004-08-03	2008-07-30	Biorexis Pharmaceutical Corp	Combination therapy using transferrin fusion proteins comprising GLP-1
WO2006049983A2 (en)	2004-10-27	2006-05-11	Biorexis Pharmaceutical Corporation	Peptide yy modified transferrin fusion proteins
EP1858546A4 (de) *	2005-03-04	2009-03-04	Biorexis Pharmaceutical Corp	Modifizierte transferrinfusionsproteine

2007
- 2007-07-13 KR KR1020097003679A patent/KR101193722B1/ko not_active Expired - Fee Related
- 2007-07-13 AT AT07789496T patent/ATE524493T1/de not_active IP Right Cessation
- 2007-07-13 EP EP07789496A patent/EP2046826B1/de not_active Not-in-force
- 2007-07-13 CA CA002658654A patent/CA2658654A1/en not_active Abandoned
- 2007-07-13 WO PCT/IB2007/002047 patent/WO2008012629A2/en not_active Ceased
- 2007-07-13 ES ES07789496T patent/ES2371495T3/es active Active
- 2007-07-13 AU AU2007278994A patent/AU2007278994B2/en not_active Ceased
- 2007-07-13 MX MX2009001066A patent/MX2009001066A/es active IP Right Grant
- 2007-07-13 CN CN2007800336434A patent/CN101511868B/zh not_active Expired - Fee Related
- 2007-07-13 JP JP2009521363A patent/JP5102833B2/ja not_active Expired - Fee Related
- 2007-07-13 DK DK07789496.2T patent/DK2046826T3/da active
- 2007-07-23 AR ARP070103267A patent/AR062030A1/es not_active Application Discontinuation
- 2007-07-23 PA PA20078738401A patent/PA8738401A1/es unknown
- 2007-07-23 PE PE2007000955A patent/PE20080733A1/es not_active Application Discontinuation
- 2007-07-23 TW TW096126804A patent/TW200821327A/zh unknown
- 2007-07-23 UY UY30497A patent/UY30497A1/es not_active Application Discontinuation
- 2007-07-23 GT GT200700059A patent/GT200700059A/es unknown
- 2007-07-24 CL CL200702157A patent/CL2007002157A1/es unknown
- 2007-07-24 US US11/782,030 patent/US7867972B2/en not_active Expired - Fee Related
2009
- 2009-01-22 IL IL196674A patent/IL196674A/en not_active IP Right Cessation
- 2009-02-23 NO NO20090830A patent/NO20090830L/no not_active Application Discontinuation
- 2009-02-23 ZA ZA2009/01280A patent/ZA200901280B/en unknown
2010
- 2010-11-30 US US12/956,623 patent/US8158579B2/en not_active Expired - Fee Related

Also Published As

Publication number	Publication date
EP2046826A2 (de)	2009-04-15
GT200700059A (es)	2008-07-09
CA2658654A1 (en)	2008-01-31
ZA200901280B (en)	2010-02-24
IL196674A0 (en)	2011-08-01
TW200821327A (en)	2008-05-16
JP5102833B2 (ja)	2012-12-19
HK1135112A1 (en)	2010-05-28
US7867972B2 (en)	2011-01-11
WO2008012629A3 (en)	2008-05-08
IL196674A (en)	2014-02-27
ES2371495T3 (es)	2012-01-03
US20090239795A1 (en)	2009-09-24
JP2009544301A (ja)	2009-12-17
AU2007278994A1 (en)	2008-01-31
PE20080733A1 (es)	2008-06-14
CL2007002157A1 (es)	2008-02-01
MX2009001066A (es)	2009-02-05
AR062030A1 (es)	2008-08-10
DK2046826T3 (da)	2011-10-24
KR20090033906A (ko)	2009-04-06
CN101511868B (zh)	2013-03-06
US20110245178A1 (en)	2011-10-06
ATE524493T1 (de)	2011-09-15
US8158579B2 (en)	2012-04-17
WO2008012629A2 (en)	2008-01-31
AU2007278994B2 (en)	2013-08-15
KR101193722B1 (ko)	2013-01-11
CN101511868A (zh)	2009-08-19
EP2046826B1 (de)	2011-09-14
PA8738401A1 (es)	2009-02-09
UY30497A1 (es)	2008-02-29

Legal Events

Date	Code	Title	Description
2017-02-27	FC2A	Withdrawal, rejection or dismissal of laid open patent application

Publication	Publication Date	Title
WO2008012629A3 (en)	2008-05-08	Exendin fusion proteins
Zheng et al.	2013	Development of new thioester equivalents for protein chemical synthesis
EA201001357A1 (ru)	2011-04-29	Слитые конструкции и конъюгаты лекарственного средства
UA97516C2 (ru)	2012-02-27	Полностью человеческое моноклональное антитело против vap-1
EP2070946A3 (de)	2009-09-09	Erfindung betreffend GLP-1 und Exendin
Huang et al.	2015	Site selective azo coupling for peptide cyclization and affinity labeling of an SH3 protein
Zhao et al.	2016	Recombinant production of medium-to large-sized peptides in Escherichia coli using a cleavable self-aggregating tag
Malins et al.	2015	Synthesis of β-thiol phenylalanine for applications in one-pot ligation–desulfurization chemistry
WO2008033395A3 (en)	2008-05-15	Melanocortin and transferrin fusion proteins
GB2431583A (en)	2007-05-02	Combination therapy using transferrin fusion proteins comprising GLP-1
UA100682C2 (ru)	2013-01-25	АНТИТЕЛО, КОТОРОЕ НЕЙТРАЛИЗУЕТ ЧЕЛОВЕЧЕСКИЙ ЦИТОМЕГАЛОВИРУС (hCMV), И ЕГО ПРИМЕНЕНИЕ
NO20064059L (no)	2006-11-02	Albumin fusjonsproteiner
MX2011008094A (es)	2012-02-13	Polipeptidos recombinantes extendidos y composiciones que comprenden los mismos.
EP4450523A3 (de)	2025-03-12	Bindungsfusionsproteine, bindungsfusionsprotein-arzneimittelkonjugate, xten-arzneimittelkonjugate sowie verfahren zur herstellung und verwendung davon
UA102503C2 (en)	2013-07-25	Interleukin-13 binding proteins
EA201290722A1 (ru)	2013-05-30	Рекомбинантный белок эксендина-4 и его аналога, способ их приготовления и применение
WO2008000516A3 (en)	2008-03-27	IMPROVED sgp130Fc DIMERS
WO2006128668A3 (en)	2007-02-22	Coagulation factor x polypeptides with modified activation properties
Wang et al.	2012	Ubiquitin-intein and SUMO2-intein fusion systems for enhanced protein production and purification
WO2010018444A3 (en)	2010-05-14	An expression vector and a method thereof
WO2007115724A3 (de)	2008-03-20	Method of increasing the in vivo recovery of therapeutic polypeptides
Gao et al.	2010	Soluble cytoplasmic expression, rapid purification, and characterization of cyanovirin-N as a His-SUMO fusion
Xu et al.	2017	Modified human glucagon-like peptide-1 (GLP-1) produced in E. coli has a long-acting therapeutic effect in type 2 diabetic mice
Gagliardo et al.	2008	Production of biologically active forms of recombinant hepcidin, the iron‐regulatory hormone
Albertsen et al.	2013	Recombinant production of peptide C-terminal α-amides using an engineered intein